Cell Therapy for Refractory Angina: A Reappraisal
Beatrice Bassetti1, Patrizia Nigro1, Valentina Catto2
1Unità di Biologia Vascolare e Medicina Rigenerativa, Centro Cardiologico Monzino IRCCS, Via Carlo Parea 4, 20138 Milan, Italy.
Abstract:
Cardiac cell-based therapy has emerged as a novel therapeutic option for patients dealing with untreatable refractory angina (RA). However, after more than a decade of controlled studies, no definitive consensus has been reached regarding clinical efficacy. Although positive results in terms of surrogate endpoints have been suggested by early and phase II clinical studies as well as by meta-analyses, the more recent reports lacked the provision of definitive response in terms of hard clinical endpoints. Regrettably, pivotal trials designed to conclusively determine the efficacy of cell-based therapeutics in such a challenging clinical condition are therefore still missing. Considering this, a comprehensive reappraisal of cardiac cell-based therapy role in RA seems warranted and timely, since a number of crucial cell- and patient-related aspects need to be systematically analysed. As an example, the large variability in efficacy endpoint selection appears to be a limiting factor for the advancement of cardiac cell-based therapy in the field. This review will provide an overview of the key elements that may have influenced the results of cell-based trials in the context of RA, focusing in particular on the understanding at which the extent of angina-related endpoints may predict cell-based therapeutic efficacy.
Insights
Cardiac cell-based therapy shows promise for refractory angina (RA), but definitive clinical evidence is lacking. Further analysis of endpoints is crucial to determine its true efficacy in treating RA patients.
Area of Science:
- Cardiology
- Regenerative Medicine
- Clinical Trials
Background:
- Cardiac cell-based therapy is a potential treatment for refractory angina (RA).
- Despite over a decade of research, definitive consensus on its clinical efficacy remains elusive.
- Early studies and meta-analyses suggest positive surrogate endpoint results, but recent reports lack hard clinical endpoint data.
Purpose of the Study:
- To reappraise the role of cardiac cell-based therapy in refractory angina.
- To identify key factors influencing trial outcomes, particularly endpoint selection.
- To analyze how angina-related endpoints predict therapeutic efficacy.
Main Methods:
- Review of existing clinical studies and meta-analyses on cardiac cell-based therapy for RA.
- Systematic analysis of cell- and patient-related aspects impacting trial results.
- Focus on the predictive value of angina-related endpoints for treatment efficacy.
Main Results:
- A significant variability in the selection of efficacy endpoints complicates the assessment of cardiac cell-based therapy.
- Pivotal trials are needed to conclusively establish the effectiveness of cell-based therapeutics in RA.
- The current evidence base is insufficient to confirm hard clinical endpoint benefits.
Conclusions:
- A comprehensive reappraisal of cardiac cell-based therapy for RA is timely and necessary.
- Standardizing endpoint selection is critical for advancing this therapeutic field.
- Further research must focus on demonstrating efficacy using robust clinical endpoints.
Related Concept Videos
01:30Angina I: Introduction
01:27Angina II: Classification
01:26Angina IV: Management
01:20Angina V: Nursing Management
01:29Angina III: Clinical Manifestations and Assessment
00:59Gene Therapy